Statin Reduces Heart Burden –SundayStar, March 19, 2006

A new study indicates that intensive statin therapy may partially reverse plaque build-up in arteries.

A new study presented recently at the American College of Cardiology's 5th Annual Scientific Session
(ACC06) demonstrates, for the first time, that very intensive cholesterol lowering with a statin drug can
regress (partially reverse) the build-up of plaque in the coronary arteries.

This finding has never before been observed in a study using statin drugs, the
most commonly used cholesterol lowering treatment Previous research had indicated that intensive statin therapy could prevent the progression of coronary atherosclero¬sis, or arterial plaque build-up, but not actually reduce disease burden. ACe.06 is the premier cardiovascular medical meet¬ing, bringing together more than 30,000 cardiologists to further breakthroughs in cardiovascular medicine.

CLICK HERE to buy your drugs from the comfort of your home and enjoy discounted prices.


The intense statin therapy used in this study resulted in significant regression of atherosclerosis as measured by intravascu¬lar ultrasound (IVUS), a technique in which a tiny ultrasound probe is inserted into the coronary arteries to measure plaque.

The study showed that regression occurred for all three pre-specified IVUS measures of disease burden. The mean baseline LOL cholesterol of 130.4 mg/dL dropped to 60.8 mg/dL in the study patients, a reduction of 53.2%. This is the largest reduction in cholesterol ever observed in a major statin outcome trial. Mean HDL cholesterol (43.1 mg/dL at baseline) increased to 49.0 mg/dL, a 14.7% increase, which was also unprecedented. The arterial plaque overall was reduced by 6.8 to 9.1 % for the various measures of dis¬ease burden

CLICK HERE to buy your drugs here from the comfort of your home and enjoy discounted prices.

This study was known by the acronym of ASTEROID (A Study To Evaluate the Effect of Rosuvastatin On Intravascular Ultrasound-Derived Coronary Atheroma Burden Trial). The trial was conducted at 53 community and tertiary care centres in the United States, Canada, Europe, and Australia.

A total of 507 patients had baseline intravascular ultrasound (IVUS) examina- . tion and received 40 mg daily of rosuvas¬tatin. IVUS proVides a precise and repro¬ducible method for determining the change in plaque, or atheroma, burden during treatment Atherosclerosis progres¬sion was assessed at baseline and after at 24 months of treatment "Previous similar studies with statins have shown slowing of coronary disease, but not regression.

This regimen signifi¬cantly lowered bad cholesterol, and sur¬prisingly' markedly increased good choles¬terollevels," said Steven Nissen, M.D., F.A.C.C., of the Cleveland Clinic and lead author of the study. Dr Nissen is also President -Elect of the American college of Cardiology. "We conclude that very low LOL levels (below current guidelines), when accompanied by raised HDL, can regress, or partially reverse, the plaque buildup in the coronary arteries."

CLICK HERE to buy your drugs from the comfort of your home and enjoy discounted prices.